Updates in Surgery

, Volume 67, Issue 4, pp 383–387 | Cite as

Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution

  • Mirko Barone
  • Decio Di Nuzzo
  • Giuseppe Cipollone
  • Pierpaolo Camplese
  • Felice Mucilli
Review Article


Though the actual incidence of an adrenal oligometastasis is between 1.5 and 3.5 %, secondary adrenal neoplasms occur in less than 10 % patients with non-small cell lung cancer (NSCLC). According to 7° ed. TNM staging system, the presence of an adrenal metastasis (M1b disease) configures stage IV, which is usually associated with poor prognosis. We evaluated if metastasectomy in selected patients with oligometastatic disease improves overall survival. A 15-year retrospective study concerning patients with NSCLC was performed and an oligometastatic disease was found in 1.61 % of the patients. 18 adrenalectomies were performed. Clustering the population according to different therapeutic strategies, a benefit in terms of survival was found in patients who underwent adrenalectomy. A statistical relevance was found, indeed, between adrenalectomy (p < 0.01), metachronous disease (p < 0.01), the presence of a homolateral disease (p < 0.05) and overall survival. Adrenalectomy should be offered in selected patients with oligometastatic disease.


Lung cancer Metastatic disease Adrenalectomy 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

The article is in accordance with ethical standards.

Research involving human participants and/or animals

The article does not contain any studies with human participants performed by the authors.

Informed consent

For this type of study, no formal consent is not required. It is an anonymous study referring only to clinical data.


  1. 1.
    Brunt LM, Moley JF (2001) Adrenal incidentaloma. World J Surg 25:905–913PubMedCrossRefGoogle Scholar
  2. 2.
    Allard P, Yankaskas BC, Fletcher RH et al (1990) Sensitivity and specificity of computed tomography for the detection of adrenal metastatic lesions among 91 autopsied lung cancer patients. Cancer 66:457–462PubMedCrossRefGoogle Scholar
  3. 3.
    Karanikiotis C, Tentes AA, Markakidis S et al (2004) Large bilateral adrenal metastases in non-small cell lung cancer. World J Surg Oncol 2:37PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lo CY, van Heerden JA, Soreide JA et al (1996) Adrenalectomy for metastatic disease to the adrenal glands. Br J Surg 83:528–531PubMedCrossRefGoogle Scholar
  5. 5.
    Kebebew E, Siperstein AE, Clark OH, Duh QY (2002) Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch Surg 137:948–951PubMedCrossRefGoogle Scholar
  6. 6.
    Siemer S, Lehmann J, Kamradt J et al (2004) Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol 171:2155–2159PubMedCrossRefGoogle Scholar
  7. 7.
    Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 3:74–85PubMedCrossRefGoogle Scholar
  8. 8.
    Mohammad K, Sadikot RT (2009) Adrenal insufficiency as a presenting manifestation of non small cell lung cancer. South Med J 102:665–667PubMedCrossRefGoogle Scholar
  9. 9.
    Ettinghausen S, Burt ME (1991) Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer. J Clin Oncol 9:1462–1466PubMedGoogle Scholar
  10. 10.
    Porte HL, Roumilhac D, Graziana JP, Eraldi L, Cordonier C, Puech P, Wurtz AJ (1998) Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg 65:331–335PubMedCrossRefGoogle Scholar
  11. 11.
    Muñoz A, López-Vivanco G, Mañé JM et al (2006) Metastatic non-small-cell lung carcinoma successfully treated with pre-operative chemotherapy and bilateral adrenalectomy. Jpn J Clin Oncol 36:731–734PubMedCrossRefGoogle Scholar
  12. 12.
    Raviv G, Klein E, Yellin A, Schneebaum S, Ben-Ari G (1990) Surgical treatment of solitary adrenal metastases from lung carcinoma. J Surg Oncol 4:123–131CrossRefGoogle Scholar
  13. 13.
    Higashiyama M, Doi O, Kodama K, Yokouchi H, Imaoka S, Koyama H (1994) Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy. Int Surg 79:124–135Google Scholar
  14. 14.
    Beitler AL, Urschel JD, Velagapudi SR, Takita H (1998) Surgical management of adrenal metastases from lung cancer. J Surg Oncol 69:54–57PubMedCrossRefGoogle Scholar
  15. 15.
    Lubikowski J, Uminski M, Andrysiak-Mamos E et al (2010) From open to laparoscopic adrenalectomy: thirty years’ experience of one medical centre. Endokrynol Pol 61(1):94–101Google Scholar
  16. 16.
    Marangos IP, Kazaryan AM, Rosseland AR et al (2009) Should we use laparoscopic adrenalectomy for metastases? Scandinavian multicenter study. J Surg Oncol 100:43–47PubMedCrossRefGoogle Scholar
  17. 17.
    Napolitano L, Mucilli F, Gargano E, Sacco R, Napolitano AM (2001) Surgical treatment of isolated adrenal matastasis from lung carcinoma. G Chir 22:243–246PubMedGoogle Scholar
  18. 18.
    Brunt LM (2002) The positive impact of laparoscopic adrenalectomy on complications of adrenal surgery. Surg Endosc 16:252–257PubMedCrossRefGoogle Scholar
  19. 19.
    Lam KY, Lo CY (2002) Metastatic tumors of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol 56:95–101CrossRefGoogle Scholar
  20. 20.
    Rosoff JS, Otto BJ, Del Pizzo JJ (2010) The emerging role of robotics in adrenal surgery. Curr Urol Rep 11:38–43PubMedCrossRefGoogle Scholar
  21. 21.
    Yuh B et al (2012) Combined robotic lobectomy and adrenalectomy for lung cancer and solitary adrenal metastasis. JSLS 16:173–177.ùGoogle Scholar
  22. 22.
    Lo SS, Fakiris AJ, Chang EL et al (2010) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7(1):44–54PubMedCrossRefGoogle Scholar
  23. 23.
    Iyengar P, Timmerman RD (2012) Stereotactic ablative radiotherapy for non-small cell lung cancer: rationale and outcomes. J Natl Compr Canc Netw 10(12):1514–1520PubMedGoogle Scholar
  24. 24.
    Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1107PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Weickhardt AJ, Scheier B, Burke JM et al (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7(12):1807–1814PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Villaruz LC, Kubicek GJ, Socinski MA (2012) Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep 14(4):333–341PubMedCrossRefGoogle Scholar
  27. 27.
    Kelsey CR, Salama JK (2013) Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies. Surg Oncol Clin N Am 22(3):463–481PubMedCrossRefGoogle Scholar
  28. 28.
    Sancho JJ, Triponez F, Montet X, Sitges-Serra A (2011) Surgical management of adrenal metastases. Langenbecks Arch Surg 397:179–194PubMedCrossRefGoogle Scholar
  29. 29.
    Milgrom SA, Goodman KA (2012) The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. J Surg Oncol 106(5):647–650PubMedCrossRefGoogle Scholar
  30. 30.
    Casamassima F, Livi L, Masciullo S et al (2012) Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys 82(2):919–923PubMedCrossRefGoogle Scholar
  31. 31.
    Holy R, Piroth M, Pinkawa M, Eble MJ (2011) Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 187(4):245–251PubMedCrossRefGoogle Scholar
  32. 32.
    Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83(3):878–886PubMedCrossRefGoogle Scholar
  33. 33.
    Salama JK, Hasselle MD, Chmura SJ et al (2012) Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118(11):2962–2970PubMedCrossRefGoogle Scholar
  34. 34.
    Iyengar P, Kavanagh BD, Wardak Z et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32(34):3824–3830PubMedCrossRefGoogle Scholar
  35. 35.
    Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(suppl 1):5–13PubMedCrossRefGoogle Scholar
  36. 36.
    Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29PubMedCrossRefGoogle Scholar
  37. 37.
    Tanvetyanon T, Robinson LA, Schell MJ et al (2008) Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 26(7):1142–1147PubMedCrossRefGoogle Scholar
  38. 38.
    Sastry P, Tocock A, Coonar AS (2014) Adrenalectomy for isolated metastasis from operable non small cell lung cancer. Inter CardioVasc Thor Surg 18:495–498CrossRefGoogle Scholar
  39. 39.
    Raz DJ, Lanuti M, Gaissert HC et al (2011) Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg 92:1788–1793PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Surgery (SIC) 2015

Authors and Affiliations

  • Mirko Barone
    • 1
  • Decio Di Nuzzo
    • 1
  • Giuseppe Cipollone
    • 1
  • Pierpaolo Camplese
    • 1
  • Felice Mucilli
    • 1
  1. 1.Department of General and Thoracic SurgeryUniversity Hospital “SS. Annunziata”ChietiItaly

Personalised recommendations